Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients

References

• Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID19 challenge for modern med-icine. Cardiol J. 2020;27(2):175–183.
   PubMedGoogle Scholar
• Kulak K, Wieczorek K, Krupski A, et al. SARS-CoV-2 as a real threat for healthcare workers. Disaster Emerg Med J. 2020;5:110–111.
   Google Scholar
• Ruetzler K, Szarpak L, Filipiak KJ, et al. The COVID-19 pandemic – a view of the current state of the problem. Disaster Emerg Med J. 2020;5:106–107.
   Google Scholar
• Szarpak L, Pruc M, Filipiak KJ, et al. Myocarditis: a complication of COVID-19 and long-COVID-19 syndrome as a serious threat in modern cardiology. Cardiol J. 2022;29(1):178–179.
   PubMed Web of Science ®Google Scholar
• Colantuoni A, Martini R, Caprari P, et al. COVID-19 sepsis and microcirculation dysfunction. Front Physiol. 2020;11:747.
   PubMed Web of Science ®Google Scholar
• Szarpak L, Pruc M, Koda M, et al. Heart inflammation risk after COVID-19 vaccine. Cardiol J. 2021;28(6):1001–1002.
   PubMed Web of Science ®Google Scholar
• Dergaa I, Abubaker M, Souissi A, et al. Age and clini-cal signs as predictors of COVID-19 symptoms and cycle threshold value. Libyan J Med. 2022;17:2010337.
   PubMed Web of Science ®Google Scholar
• Smereka J, Szarpak L, Filipiak KJ. Modern medicine in COVID-19 era. Disaster Emerg Med J. 2020;5:103–105.
   Google Scholar
• Levenfus I, Ullmann E, Battegay E, et al. Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score. Braz J Infect Dis. 2020;24(5):458–461.
   PubMed Web of Science ®Google Scholar
• Yaman E, Demirel B, Abdurrahman Y, et al. Retrospective evaluation of laboratory findings of suspected pae-diatric COVID-19 patients with positive and negative RT-PCR. Disaster Emerg Med J. 2021;6(3):97–103.
   Google Scholar
• Samprathi M, Jayashree M. Biomarkers in COVID-19: an up-to-date review. Front Pediatr. 2020;8:607647.
   PubMed Web of Science ®Google Scholar
• Szarpak Ł, Nowak B, Kosior D, et al. Cytokines as predictors of COVID-19 severity: evidence from a meta-analysis. Pol Arch Intern Med. 2021;131(1):98–99.
   PubMedGoogle Scholar
• Szarpak L, Zaczynski A, Kosior D, et al. Evidence of diagnostic value of ferritin in patients with COVID-19. Cardiol J. 2020;27(6):886–887.
   PubMed Web of Science ®Google Scholar
• Ruetzler K, Szarpak Ł, Ładny JR, et al. D-dimer levels predict COVID-19 severity and mortality. Kardiol Pol. 2021;79(2):217–218.
   PubMed Web of Science ®Google Scholar
• Assandri R, Accordino S, Canetta C, et al. Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives. Biochem Med. 2022;32(2):020901.
   Web of Science ®Google Scholar
• Gupta D, Jain A, Chauhan M, et al. Inflammatory markers as early predictors of disease severity in COVID-19 patients admitted to intensive care units: a retrospective observational analysis. Indian J Crit Care Med. 2022;26(4):482–486.
   PubMed Web of Science ®Google Scholar
• de Roquetaillade C, Chousterman BG, Mebazaa A. Making things right! shouldn’t we screen patients with thromboembolic events for SARS-CoV-2 infection, during the pandemia? Int J Cardiol. 2021;338:286–287.
   PubMed Web of Science ®Google Scholar
• Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21(2):138–167.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Spoto S, Fogolari M, et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-adrenomedullin (MR-proADM) in bacterial infections. APMIS. 2015;123(9):740–748.
   PubMed Web of Science ®Google Scholar
• Zuur-Telgen MC, Brusse-Keizer MG, VanderValk PD, et al. Stable-state mid-range-proadrenomedullin level is a strong predictor of mortality in patients with COPD. Chest. 2014;145(3):534–541.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech. 2002;57(1):3–13.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care. 2006;10(3):R96.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816–R824.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55(19):2062–2076.
   PubMed Web of Science ®Google Scholar
• Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem. 2007;14(15):1689–1699.
   PubMed Web of Science ®Google Scholar
• Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midre-gional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester acute myocardial infarction peptide) study. J Am Coll Cardiol. 2007;49(14):1525–1532.
   PubMed Web of Science ®Google Scholar
• Önal U, Valenzuela-Sánchez F, Vandana KE, et al. Mid-Regional Pro-Adrenomedullin (MR-proADM) as a biomarker for sepsis and septic shock: narrative review. Healthcare. 2018;6(3):110.
   Web of Science ®Google Scholar
• Andrés C, Andaluz-Ojeda D, Cicuendez R, et al. MR-proADM to detect specific types of organ failure in infection. Eur J Clin Invest. 2020;50(6):e13246.
   PubMed Web of Science ®Google Scholar
• Ueda S, Nishio K, Minamino N, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med. 1999;160(1):132–136.
   PubMed Web of Science ®Google Scholar
• Elke G, Bloos F, Wilson DC, SepNet Critical Care Trials Group, et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis – a secondary analysis of a large randomised controlled trial. Crit Care. 2018;22(1):79.
   PubMedGoogle Scholar
• Tzikas S, Keller T, Ojeda FM, et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart. 2013;99(6):388–395.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, Cochrane Statistical Methods Group, et al. The cochrane collaboration’s tool for assessing risk of bias in ran-domised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Fabris M, Del Ben F, Sozio E, et al. Cytokines from bench to bedside: a retrospective study identifies a definite panel of biomarkers to early assess the risk of negative Out-come in COVID-19 patients. IJMS. 2022;23(9):4830.
   Google Scholar
• García de Guadiana-Romualdo L, Martínez Martínez M, Rodríguez Mulero MD, et al. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Int J Infect Dis. 2021;111:211–218.
   PubMed Web of Science ®Google Scholar
• Gregoriano C, Koch D, Kutz A, et al. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study. Clin Chem Lab Med. 2021;59(5):995–1004.
   PubMed Web of Science ®Google Scholar
• Indirli R, Bandera A, Valenti L, COVID-19 Network Working Group, et al. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients. Eur J Clin Invest. 2022;52(5):e13753.
   PubMed Web of Science ®Google Scholar
• Minieri ML, Di Lia M, Stella M, et al. Predictive value of MR-proADM in the risk stratification of COVID-19 patients assessed at the triage of the emergency department. EuropePMC; 2021;12(8):1971.
   Google Scholar
• Montrucchio G, Sales G, Rumbolo F, et al. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: an observational prospective study. PLOS One. 2021;16(2):e0246771.
   PubMed Web of Science ®Google Scholar
• Oblitas CM, Galeano-Valle F, Ramírez-Navarro J, et al. Mid-regional pro-adrenomedullin, me-themoglobin and carboxyhemoglobin as prognosis biomarkers in critically ill patients with COVID-19: an observational prospective study. Viruses. 2021;13(12):2445.
   PubMed Web of Science ®Google Scholar
• van Oers JAH, Kluiters Y, Bons JAP, et al. Endo-thelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to pre-dict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: a prospective cohort study. J Crit Care. 2021;66:173–180.
   PubMed Web of Science ®Google Scholar
• Astapovskii AA, Drozdov VN, Shikh EV, et al. Prognostic value of proadrenomedullin in patients with COVID-19 pneumonia. Front Med. 2022;9:961071.
   Web of Science ®Google Scholar
• Atallah NJ, Panossian VS, Atallah CJ, et al. Mid-regional proadrenomedullin biomarker predicts coronavirus disease 2019 clinical outcomes: a US-based cohort study. Open Forum Infect Dis. 2022;9(9):ofac423.
   PubMed Web of Science ®Google Scholar
• de Montmollin E, Peoc’h K, Marzouk M, et al. Mid-regional pro-adrenomedullin as a prognostic factor for severe COVID-19 ARDS. Antibiotics. 2022;11(9):1166.
   Google Scholar
• Mangioni D, Oggioni M, Chatenoud L, et al. Prognostic value of mid-region proadrenomedullin and in vitro interferon gamma production for in-hospital mortality in patients with COVID-19 pneumonia and respiratory failure: an observational prospective study. Viruses. 2022;14(8):1683.
   PubMed Web of Science ®Google Scholar
• Moore N, Williams R, Mori M, et al. Mid-regional proadrenomedullin (MR-proADM), C- reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting. J Clin Pathol. 2022. jclinpath-2021-207750.
   Web of Science ®Google Scholar
• Popov D, Borovkova U, Rybka M, et al. Mid-regional pro-adrenomedullin as a predictor of in-hospital mortality in adult patients with COVID-19: a single-centre prospective study. Anaesthesiol Intensive Ther. 2022;54(3):242–246.
   PubMed Web of Science ®Google Scholar
• Szarpak L, Jaguszewski MJ, Pruc M, et al. Myocardial injury: a future challenge for long-COVID-19 complications. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):618.
   PubMed Web of Science ®Google Scholar
• Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;173(4):268–277.
   PubMed Web of Science ®Google Scholar
• Nägele MP, Haubner B, Tanner FC, et al. Endothelial dysfunction in COVID-19: current find-ingsand therapeutic implications. Atherosclerosis. 2020;314:58–62.
   PubMed Web of Science ®Google Scholar
• Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038–3044.
   PubMed Web of Science ®Google Scholar
• Hupf J, Mustroph J, Hanses F, et al. RNA‐expression of adrenomedullin is increased in patients with severe COVID‐19. Crit Care. 2020;24(1):527.
   PubMed Web of Science ®Google Scholar
• García de Guadiana-Romualdo L, Calvo Nieves MD, Rodríguez Mulero MD, et al. MR‐proADM as marker of endotheliitis predicts COVID‐19 severity. Eur J Clin Invest. 2021;51(5):e13511.
   PubMed Web of Science ®Google Scholar
• Bowe B, Xie Y, Xu E, et al. Kidney outcomes in long COVID. J Am Soc Nephrol. 2021;32(11):2851–2862.
   PubMed Web of Science ®Google Scholar
• Nucera G, Chirico F, Rafique Z, et al. Need to update cardiological guidelines toprevent COVID-19 related myocardial infarction and ischemic stroke. Cardiol J. 2022;29(1):174–175.
   PubMed Web of Science ®Google Scholar
• Martin-Fernandez M, Vaquero-Roncero LM, Almansa R, et al. Endothelial dysfunction is an early indicator of sepsis and neutrophil degranulation of septic shock in surgical patients. BJS Open. 2020;4(3):524–534.
   PubMed Web of Science ®Google Scholar